A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas
3.1.1 Patients must be at least 3 years of age and ≤ 18 years of age at the time of study
3.1.2 Patients must have clinical findings and neuroradiographic findings consistent with
diffuse intrinsic pontine glioma. Histologic confirmation of diagnosis is not required for
diffuse intrinsic pontine gliomas. A copy of the MRI must be submitted for verification of
3.1.3 Patients must have received conventional radiation therapy of total radiation dosage
ranging from 5400 to 6000 cGy administered in fractions of 150 to 200 cGy over 6 weeks.
3.1.4 Treatment must start 14 to 28 days after completion of conventional radiation
3.1.5 Patients receiving systemic corticosteroid therapy must be on a tapering or stable
low (2 mg twice daily) dose of dexamethasone two weeks after conventional radiation.
3.1.6 Patients life expectancy must be greater or equal to 8 weeks.
3.1.7 Patients must have a performance status (Lansky or Karnofsky) ≥ 50.
3.1.8 Platelet count ≥ 100,000/ mm3.
3.1.9 Hemoglobin ≥ 10 g/dL.
3.1.10 Creatinine ≤ 2.0 mg/dL.
3.1.11 Serum bilirubin ≤ 5.0 mg/dL.
3.1.12 If female, patients of childbearing potential must have a negative serum β-hCG
3.1.13 Both male and female patients must agree to use hormonal or barrier birth control
with spermicidal gel to avoid pregnancy during the study.
3.1.14 The patient and/or their guardian must have the ability to understand and the
willingness to sign a written informed consent document.
3.2.1 Prior therapy for diffuse intrinsic pontine glioma, aside from surgery, conventional
radiation, and temozolomide.
3.2.2 Use of any experimental drug for any reason within the 60 days prior to treatment.
3.2.3 Active infection requiring treatment.
3.2.4 Known medical condition that, in the opinion of the Investigator, would compromise
the patient's ability to participate in the study. This would include chronic active
hepatitis infection, known immunosuppressive disease or concurrent neurodegenerative
3.2.5 Known allergy or hypersensitivity to any of the components of the vaccine treatment,
including GM-CSF, yeast derived products, or a history of anaphylactic reactions to
3.2.6 Pregnant women and women who are breast-feeding.